down arrow

Stereotaxis, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US85916J4094
USD
2.43
0.1 (4.29%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.322.46

52 Week

1.543.59
Valuation
Technical
Day's Volume

CASH

364.77 k

Shareholding (Mar 2025)

FII

1.43%

Held by 27 FIIs

DII

89.13%

Held by 14 DIIs

Promoter

0.00%

How big is Stereotaxis, Inc.?

22-Jun-2025

As of Jun 18, Stereotaxis, Inc. has a market capitalization of 195.23 million and reported net sales of 27.51 million, with a net loss of 25.35 million over the latest four quarters. Shareholder's funds are at 11.43 million, and total assets amount to 46.72 million.

As of Jun 18, Stereotaxis, Inc. has a market capitalization of 195.23 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 27.51 million for the latest four quarters, while the net profit for the same period was a loss of 25.35 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 11.43 million and total assets amounting to 46.72 million.

Read More

What does Stereotaxis, Inc. do?

22-Jun-2025

Stereotaxis, Inc. is a U.S. healthcare technology company specializing in robotic cardiology instrument navigation systems, with a market cap of $195.23 million and recent net sales of $7 million. The company reported a net loss of $6 million for the quarter ending March 2025.

Overview: <BR>Stereotaxis, Inc. is a United States-based healthcare technology company engaged in the development of robotic cardiology instrument navigation systems, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 195.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.24 <BR>Return on Equity: -310.19% <BR>Price to Book: 23.88<BR><BR>Contact Details: <BR>Address: 4320 Forest Park Ave Ste 100, ST. LOUIS MO: 63108-2979 <BR>Tel: 1 314 6786100 <BR>Fax: 1 314 6786159 <BR>Website: http://www.stereotaxis.com

Read More

Who are in the management team of Stereotaxis, Inc.?

22-Jun-2025

As of March 2022, the management team of Stereotaxis, Inc. includes Chairman and CEO David Fischel, Lead Independent Director David Benfer, Directors Nathan Fischel, Joseph Kiani, Ross Levin, and Independent Director Arun Menawat. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Stereotaxis, Inc. includes the following individuals:<BR><BR>- Mr. David Fischel, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. David Benfer, who is the Lead Independent Director.<BR>- Dr. Nathan Fischel, who is a Director.<BR>- Mr. Joseph Kiani, who is an Independent Director.<BR>- Mr. Ross Levin, who is also an Independent Director.<BR>- Dr. Arun Menawat, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Stereotaxis, Inc. overvalued or undervalued?

20-Sep-2025

As of May 9, 2019, Stereotaxis, Inc. is considered a risky investment due to its high Price to Book Value of 23.67, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -310.19%, especially when compared to peers like Bioventus and Semler Scientific, despite a year-to-date return of 22.81% against the S&P 500's 12.22%.

As of 9 May 2019, the valuation grade for Stereotaxis, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company is overvalued, as evidenced by its high Price to Book Value of 23.67 and negative EV to EBIT and EV to EBITDA ratios of -7.08 and -7.42, respectively. Additionally, the Return on Equity (ROE) is alarmingly low at -310.19%, reflecting significant financial distress.<BR><BR>In comparison to its peers, Stereotaxis, Inc. exhibits a notably worse valuation profile; for instance, Bioventus, Inc. has a P/E ratio of 72.81, while Semler Scientific, Inc. is considered attractive with a P/E ratio of 32.26. The stock has shown mixed performance against the S&P 500, with a year-to-date return of 22.81% compared to the index's 12.22%, but a disappointing 5-year return of -25.73% versus the S&P 500's impressive 96.61%.

Read More

Is Stereotaxis, Inc. technically bullish or bearish?

20-Sep-2025

As of August 8, 2025, Stereotaxis, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year, but underperforming over longer periods.

As of 8 August 2025, the technical trend for Stereotaxis, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. However, the weekly RSI is bearish, indicating some short-term weakness. The daily moving averages are bullish, and the KST is bullish on both weekly and monthly time frames. The Bollinger Bands show a mildly bullish stance on both weekly and monthly periods. The Dow Theory indicates a mildly bullish trend on the weekly chart but no trend on the monthly.<BR><BR>In terms of performance, Stereotaxis has outperformed the S&P 500 year-to-date with a return of 22.81% compared to the S&P's 12.22%, and over the past year, it has returned 43.59% versus the S&P's 17.14%. However, over longer periods, such as 3 years and 5 years, it has significantly underperformed the benchmark.<BR><BR>Overall, the current technical stance is bullish, driven primarily by the MACD and moving averages, despite some mixed signals from the RSI and Dow Theory.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 262 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.94

stock-summary
Return on Equity

-345.88%

stock-summary
Price to Book

38.85

Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.96%
0%
-11.96%
6 Months
6.11%
0%
6.11%
1 Year
9.95%
0%
9.95%
2 Years
38.86%
0%
38.86%
3 Years
5.65%
0%
5.65%
4 Years
-58.6%
0%
-58.6%
5 Years
-46.59%
0%
-46.59%

Stereotaxis, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Stereotaxis, Inc. Hits New 52-Week High of $3.58, Marking Key Milestone

Stereotaxis, Inc. Hits New 52-Week High of $3.58, Marking Key Milestone

Stereotaxis, Inc. has achieved a new 52-week high of USD 3.58, significantly up from its low of USD 1.54. Despite this milestone, the company has seen a slight decline in performance over the past year, with a market capitalization of USD 262 million and notable financial challenges.

Read More
Stereotaxis, Inc. Hits New 52-Week High at USD 3.37

Stereotaxis, Inc. Hits New 52-Week High at USD 3.37

Stereotaxis, Inc. has achieved a new 52-week high of USD 3.37, contrasting with its 52-week low of USD 1.54. Despite this milestone, the company has seen a 1-year performance decline of 11.17%. Currently, Stereotaxis is loss-making, with a market capitalization of USD 262 million.

Read More
Stereotaxis, Inc. Hits New 52-Week High at $3.33

Stereotaxis, Inc. Hits New 52-Week High at $3.33

Stereotaxis, Inc. has achieved a new 52-week high of USD 3.33 as of October 6, 2025, despite a 1-year performance decline of 7.82%. The company, with a market capitalization of USD 262 million, is currently loss-making and does not offer dividends, reflecting challenges in the Pharmaceuticals & Biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.96%
EBIT Growth (5y)
-220.99%
EBIT to Interest (avg)
-17.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.24
Sales to Capital Employed (avg)
1.83
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
55.65%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
23.67
EV to EBIT
-7.08
EV to EBITDA
-7.42
EV to Capital Employed
-95.28
EV to Sales
6.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-310.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (9.44%)

Foreign Institutions

Held by 27 Foreign Institutions (1.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 17.33% vs 19.05% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 34.48% vs 22.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.80",
          "val2": "7.50",
          "chgp": "17.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-5.60",
          "chgp": "35.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.80",
          "val2": "-5.80",
          "chgp": "34.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-452.00%",
          "val2": "-793.50%",
          "chgp": "34.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.37% vs -4.63% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.94% vs -13.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.90",
          "val2": "26.80",
          "chgp": "0.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.80",
          "val2": "-21.20",
          "chgp": "-12.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.00",
          "val2": "-20.70",
          "chgp": "-15.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-919.10%",
          "val2": "-815.80%",
          "chgp": "-10.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
8.80
7.50
17.33%
Operating Profit (PBDIT) excl Other Income
-3.60
-5.60
35.71%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.80
-5.80
34.48%
Operating Profit Margin (Excl OI)
-452.00%
-793.50%
34.15%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 17.33% vs 19.05% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 34.48% vs 22.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
26.90
26.80
0.37%
Operating Profit (PBDIT) excl Other Income
-23.80
-21.20
-12.26%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.00
-20.70
-15.94%
Operating Profit Margin (Excl OI)
-919.10%
-815.80%
-10.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.37% vs -4.63% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -15.94% vs -13.11% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Stereotaxis, Inc. stock-summary
stock-summary
Stereotaxis, Inc.
Pharmaceuticals & Biotechnology
Stereotaxis, Inc. is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab. The Stereotaxis platform helps physicians to provide patient care with robotic precision and enhanced integration of procedural information. The Company’s Epoch solution includes the Niobe ES remote magnetic navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems, and the Vdrive robotic navigation system and consumables. The Niobe ES remote magnetic navigation system includes the Navigant software user interface and the QuikCAS catheter advancement system. The Vdrive robotic navigation system with Niobe ES magnetic navigation system provides navigation and stability for diagnostic and ablation devices.
Company Coordinates stock-summary
Company Details
4320 Forest Park Ave Ste 100 , ST. LOUIS MO : 63108-2979
stock-summary
Tel: 1 314 6786100
stock-summary
http://www.stereotaxis.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."